Cancer in pregnancy: Fetal and neonatal outcomes

Clinical Obstetrics and Gynecology

Volumn 54, Issue 4, 2011, Pages 574-590

  Backes, Carl H ^a   Moorehead, Pamela A ^a   Nelin, Leif D ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

cancer; fetus; neonate; Pregnancy

Indexed keywords

AMINOPTERIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BUSULFAN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GADOLINIUM; IDARUBICIN; METHOTREXATE; PACLITAXEL; SORAFENIB; TECHNETIUM 99M; TRASTUZUMAB; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADJUVANT THERAPY; AMNION FLUID; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CARDIOMYOPATHY; CARDIOTOXICITY; CAVA VEIN DISEASE; CHILD HEALTH; CLEFT PALATE; COMPUTER ASSISTED TOMOGRAPHY; CONCEPTION; DRUG SAFETY; ECTOPIC PREGNANCY; ESOPHAGUS ATRESIA; EYE MALFORMATION; FEEDING DISORDER; FEMALE GENITAL TRACT CANCER; FETUS DEVELOPMENT; FETUS GROWTH; FETUS MALFORMATION; FETUS RISK; FIRST TRIMESTER PREGNANCY; FLUOROSCOPY; FOLLOW UP; GESTATIONAL AGE; HEARING LOSS; HUMAN; INTELLIGENCE QUOTIENT; INTRAUTERINE GROWTH RETARDATION; IONIZING RADIATION; JAUNDICE; KIDNEY AGENESIS; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; LEUKOMALACIA; LOW BIRTH WEIGHT; MATERNAL CARE; MELANOMA; MENTAL DEFICIENCY; NEUROBLASTOMA; NEWBORN DEATH; NEWBORN INTENSIVE CARE; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGOHYDRAMNIOS; OVARY CANCER; PERINATAL MORTALITY; PREGNANCY OUTCOME; PREGNANT WOMAN; PRENATAL DIAGNOSIS; PRENATAL DRUG EXPOSURE; PRENATAL GROWTH; PYLORUS STENOSIS; RADIATION DOSE; RADIATION EXPOSURE; RADIATION SAFETY; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; SARCOMA; SECOND TRIMESTER PREGNANCY; SEIZURE; SIDE EFFECT; SMALL FOR DATE INFANT; SPINE RADIOGRAPHY; SPONTANEOUS ABORTION; THIRD TRIMESTER PREGNANCY; THORAX RADIOGRAPHY; THYROID CANCER; UTERINE CERVIX CANCER;

FEMALE; FETAL DEVELOPMENT; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PREGNANCY TRIMESTERS; PREMATURE BIRTH; PRENATAL INJURIES;

EID: 80055092597     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0b013e318236e8d9     Document Type: Article

References (69)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60:277-300.
2. Pavlidis NA. Coexistence of pregnancy and malignancy. Oncologist. 2002;7: 279-287. (Pubitemid 34919954)
3. Moore K. The developing human: clinically oriented embyrology. 4th ed. W.B. Saunders Co. Philadelphia; 1988.
4. Pentheroudakis G, Pavlidis N. Cancer and pregnancy: poena magna, not anymore. Eur J Cancer. 2006;42:126-140. (Pubitemid 43083481)
5. Williams SF, Schilsky RL. Antineoplastic drugs administered during pregnancy. Semin Oncol. 2000;27:618-622.
6. Doll DC, Ringenberg QS, Yarbro JW. Antineoplastic agents and pregnancy. Semin Oncol. 1989;16:337-346. (Pubitemid 19259007)
7. Creasy RK, RR. Intrauterine Growth Restriction. Vol 4th ed. Philadelphia: WB Saunders; 1999.
8. Cardonick E, Usmani A, Ghaffar S. Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry. Am J Clin Oncol. 2010;33:221-228.
9. Briggs GCFR, Yaffe SJ. Drugs in Pregnancy and Lactation:AReference Guide to Fetal and Neonatal Risks. 8th ed. Philadelphia: Lippincott, Williams, Wilkens; 2008.
10. Ebert U, Loffler H, Kirch W. Cytotoxic therapy and pregnancy. Pharmacol Ther. 1997;74:207-220. (Pubitemid 27340586)
11. Randall T. National registry seeks scarce data on pregnancy outcomes during chemotherapy. JAMA. 1993;269:323. (Pubitemid 23018060)
12. Ring AE, Smith IE, Jones A, et al. Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. J Clin Oncol. 2005;23:4192-4197. (Pubitemid 46211325)
13. Zemlickis D, Lishner M, Degendorfer P, et al. Fetal outcome after in utero exposure to cancer chemotherapy. Arch Intern Med. 1992;152:573-576.
14. Tyson JE, Parikh NA, Langer J, et al. Intensive care for extreme prematurity-moving beyond gestational age. N Engl J Med. 2008;358:1672-1681. (Pubitemid 351549914)
15. Rosenberg A. The IUGR newborn. Semin Perinatol. 2008;32:219-224. (Pubitemid 351636317)
16. Lackman F, Capewell V, Richardson B, et al. The risks of spontaneous preterm delivery and perinatal mortality in relation to size at birth according to fetal versus neonatal growth standards. Am J Obstet Gynecol. 2001;184:946-953. (Pubitemid 32368114)
17. Gililland J, Weinstein L. The effects of cancer chemotherapeutic agents on the developing fetus. Obstet Gynecol Surv. 1983;38:6-13. (Pubitemid 15179977)
18. Van Calsteren K, Heyns L, De Smet F, et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol. 2010;28:683-689.
19. Caligiuri MA, Mayer RJ. Pregnancy and leukemia. Semin Oncol. 1989;16:388-396. (Pubitemid 19259011)
20. Tambyraja RL, Ratnam SS. The small fetus: growth-retarded and preterm. Clin Obstet Gynaecol. 1982;9:517-537.
21. Van Calsteren K, Berteloot P, Hanssens M, et al. In utero exposure to chemotherapy: effect on cardiac and neurologic outcome. J Clin Oncol. 2006;24:e16-e17.
22. Wang ML, Dorer DJ, Fleming MP, et al. Clinical outcomes of near-term infants. Pediatrics. 2004;114:372-376. (Pubitemid 39006664)
23. Khashu M, Narayanan M, Bhargava S, et al. Perinatal outcomes associated with pretermbirth at 33 to 36 weeks' gestation: a population-based cohort study. Pediatrics. 2009;123:109-113.
24. Young PC, Glasgow TS, Li X, et al. Mortality of late-preterm (near-term) newborns in Utah. Pediatrics. 2007;119: e659-e665. (Pubitemid 46407540)
25. Weisz B, Meirow D, Schiff E, et al. Impact and treatment of cancer during pregnancy. Expert Rev Anticancer Ther. 2004; 4:889-902. (Pubitemid 39359872)
26. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol. 2004;5:283-291. (Pubitemid 38541580)
27. Zemlickis D, Lishner M, Erlich R, et al. Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide. Teratog Carcinog Mutagen. 1993; 13:139-143. (Pubitemid 23253372)
28. Ostensen M, Ramsey-Goldman R. Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options? Drug Saf. 1998;19: 389-410. (Pubitemid 28505197)
29. Mir O, Berveiller P, Ropert S, et al. Use of platinum derivatives during pregnancy. Cancer. 2008;113:3069-3074.
30. Schimmel KJ, Richel DJ, van den Brink RB, et al. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev. 2004;30:181-191. (Pubitemid 38418056)
31. Aviles A, Neri N, Nambo MJ. Long-term evaluation of cardiac function in children who received anthracyclines during pregnancy. Ann Oncol. 2006;17:286-288. (Pubitemid 43160119)
32. Reynoso EE, Huerta F. Acute leukemia and pregnancy-fatal fetal outcome after exposure to idarubicin during the second trimester. Acta Oncol. 1994;33:709-710. (Pubitemid 24345383)
33. Peccatori FA, Azim HA Jr., Scarfone G, et al.Weekly epirubicin in the treatment of gestational breast cancer (GBC). Breast Cancer Res Treat. 2009;115:591-594.
34. Guarneri V, Barbieri E, Dieci MV, et al. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Cancer Treat Rev. 2010;36 (SUPPL. 3): S62-S66.
35. Azim HA Jr., Azim H, Peccatori FA. Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. Expert Rev Clin Immunol. 2010;6: 821-826.
36. Kokai Y, Cohen JA, Drebin JA, et al. Stage-and tissue-specific expression of the neu oncogene in rat development. Proc Natl Acad Sci USA. 1987;84:8498-8501.
37. Mir O, Berveiller P, Goffinet F, et al. Taxanes for breast cancer during pregnancy: a systematic review. Ann Oncol. 2010;21:425-426.
38. Banerjee S, Gore M. The future of targeted therapies in ovarian cancer. Oncologist. 2009;14:706-716.
39. Patyna S, Haznedar J, Morris D, et al. Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol. 2009;86:204-213.
40. Hahn KM, Johnson PH, Gordon N, et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer. 2006;107:1219-1226. (Pubitemid 44452769)
41. Aviles A, Neri N. Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin Lymphoma. 2001;2:173-177. (Pubitemid 34092723)
42. Brent RL. Saving lives and changing family histories: appropriate counseling of pregnant women and men and women of reproductive age, concerning the risk of diagnostic radiation exposures during and before pregnancy. Am J Obstet Gynecol. 2009;200:4-24.
43. Ratnapalan S, Bona N, Chandra K, et al. Physicians' perceptions of teratogenic risk associated with radiography and CT during early pregnancy. AJRAmJ Roentgenol. 2004;182:1107-1109. (Pubitemid 38525497)
44. Otake M, Schull WJ. In utero exposure to A-bomb radiation andmental retardation; a reassessment. Br J Radiol. 1984;57:409-414. (Pubitemid 14129700)
45. Schull W. Effects of Atomic Radiation: A Half Century of Studies from Hiroshima and Nagaski. New York: JohnWiley and Sons; 1995.
46. OtakeM, SchullWJ, Lee S. Threshold for radiation-related severe mental retardation in prenatally exposed A-bomb survivors: a re-analysis. Int J Radiat Biol. 1996;70:755-763. (Pubitemid 26426814)
47. Shore RE. Gaps in the epidemiology of in utero radiation-exposure effects. International Congress Series. 2002;1236:13-18.
48. Miller RW. Discussion: severe mental retardation and cancer among atomic bomb survivors exposed in utero. Teratology. 1999;59:234-235. (Pubitemid 29231840)
49. Chen MM, Coakley FV, Kaimal A, et al. Guidelines for computed tomography and magnetic resonance imaging use during pregnancy and lactation. Obstet Gynecol. 2008;112 (2 Pt 1):333-340.
50. Pages C, Robert C, Thomas L, et al. Management and outcome of metastatic melanoma during pregnancy. Br J Dermatol. 2010;162:274-281.
51. Wieseler KM, Bhargava P, Kanal KM, et al. Imaging in pregnant patients: examination appropriateness. Radiographics. 2010;30:1215-1229; discussion 1230-1213.
52. Clements H, DuncanKR,FieldingK, et al. Infants exposed to MRI in utero have a normal paediatric assessment at 9 months of age. Br J Radiol. 2000;73:190-194. (Pubitemid 30179228)
53. Kok RD, de Vries MM, Heerschap A, et al. Absence of harmful effects of magnetic resonance exposure at 1.5 T in utero during the third trimester of pregnancy: a follow-up study. Magn Reson Imaging. 2004;22:851-854. (Pubitemid 38962322)
54. Kikuchi S, Saito K, Takahashi M, et al. Temperature elevation in the fetus from electromagnetic exposure during magnetic resonance imaging. Phys Med Biol. 2010;55:2411-2426.
55. Kanal E, Barkovich AJ, Bell C, et al. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol. 2007;188:1447-1474. (Pubitemid 46866845)
56. Eyvazzadeh AD, Levine D. Imaging of pelvic pain in the first trimester of pregnancy. Radiol Clin North Am. 2006;44:863-877. (Pubitemid 44828721)
57. Moore C, Promes SB. Ultrasound in pregnancy. Emerg Med Clin North Am. 2004;22:697-722. (Pubitemid 39037701)
58. Adelstein SJ.Administered radionuclides in pregnancy. Teratology. 1999;59:236-239. (Pubitemid 29231841)
59. Bithell JF, StewartAM.Pre-natal irradiation and childhood malignancy: a review of British data from the Oxford Survey. Br J Cancer. 1975;31:271-287.
60. International Commission on Radiological Protection. Biological effects after prenatal irradiation (embryo and fetus). ICRP Publication 90. Ann. ICRP. 2003;22:1.
61. Brent RL, Mettler FA. Pregnancy policy. AJR Am J Roentgenol. 2004;182: 819-822; author reply 822.
62. Mazonakis M, Varveris H, Damilakis J, et al.Radiation dose to conceptus resulting from tangential breast irradiation. Int J RadiatOncol Biol Phys. 2003;55:386-391. (Pubitemid 36069097)
63. Cohen-Kerem R, Railton C, Oren D, et al. Pregnancy outcome following nonobstetric surgical intervention. Am J Surg. 2005;190:467-473. (Pubitemid 41139305)
64. Mazze RI, Kallen B. Reproductive outcome after anesthesia and operation during pregnancy: a registry study of 5405 cases. Am J Obstet Gynecol. 1989;161:1178-1185. (Pubitemid 20007677)
65. Germann N, Haie-Meder C, Morice P, et al. Management and clinical outcomes of pregnant patients with invasive cervical cancer. Ann Oncol. 2005;16:397-402. (Pubitemid 40458315)
66. Hoekstra RE, Ferrara TB, Couser RJ, et al. Survival and long-term neurodevelopmental outcome of extremely premature infants born at 23-26 weeks' gestational age at a tertiary center. Pediatrics. 2004;113 (1 Pt 1):e1-e6.
67. Fanaroff AA, Stoll BJ, Wright LL, et al. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol. 2007;196:147 e141-e148.
68. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation forwomen at risk of pretermbirth. Cochrane Database Syst Rev. 2006;3:CD004454.
69. Bartels DB, Wypij D, Wenzlaff P, et al. Hospital volume and neonatal mortality among very low birth weight infants. Pediatrics. 2006;117:2206-2214. (Pubitemid 46071267)